Abstract
Background and Aims The consequences of exercise-induced premature ventricular contractions (PVCs) in asymptomatic individuals remain unclear. This study aimed to assess the association between PVC burdens during stress testing and major adverse cardiovascular events (MACE; myocardial infarction (MI), life-threatening ventricular arrhythmia (LTVA), and heart failure (HF)), and all-cause mortality. Additional end-points were: MI, LTVA, HF and cardiovascular mortality.
Methods A neural network was developed to count PVCs from ECGs recorded during exercise (6 min) and recovery (1 min) in 48,502 asymptomatic participants from UK Biobank. Associations were estimated using multivariable Cox proportional hazard models.
Results Mean age was 56.8 (+/-8.2 years); 51.1% were female, and median follow-up was 11.5 years. Low PVC counts during exercise and recovery were both associated with MACE risk, independently from clinical factors: adjusted hazard ratio [HR]: 1.2 (2-4 exercise PVCs, p = 0.022) and HR 1.2, (1 recovery PVC, p = 0.031). Risk increased with increasing PVC count: HR 1.8 (>25 exercise PVCs, p<0.001) and HR 1.5 (≥5 recovery PVCs, p < 0.001). A similar trend was observed for all-cause mortality, although associations were only significant for higher PVC burdens: HRs: 1.4 (11-25 exercise PVCs, p = 0.007) and 1.5 (≥5 recovery PVCs, p < 0.001). Complex PVCs rhythms were associated with higher risk compared to PVC count alone. PVCs were also strongly associated with incident HF, LTVA, and cardiovascular mortality, but not MI.
Conclusion PVC count during exercise and recovery are both associated with MACE, all-cause mortality, HF, LTVAs and cardiovascular mortality, independent of clinical and exercise stress test factors, indicating a “dose response” between PVC count and risk. Complex PVCs rhythms are associated with higher risk compared to PVC count alone.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the MRC grant MR/N025083/1. PDL is supported by UCL/UCLH Biomedicine NIHR. AT and PBM and AT acknowledge the NIHR Cardiovascular Bio-medical Research Centre at Barts and QMUL, UK. JR acknowledges the "Maria Zambrano" fellow-ship support from the European Union-NextGenerationEU. AD and SVD also acknowledge support from the Wellcome Trust (223100/Z/21/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has extensive baseline and follow-up clinical, biochemical, and outcome measures and ap-proval from the North West Multi-Centre Research Ethics Committee. All participants provided in-formed consent at the time of enrolment for their data to be linked to the health record systems.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study will be made available upon reasonable request to UK Biobank
